Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Follow us on LinkedIn ... the world has attracted diverse players including academic ... The early years of nanotechnology development was dominated ... the high risks involved, which deterred private and ... evolving technology have been growing over the years, ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 ... engaged in the development of high-value and difficult to ... will be presenting at the 21 st Annual ... New York . Bertrand Liang , chief ... the company,s development programs and business strategy on Friday, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it has filed a shelf registration statement on Form ... when declared effective by the SEC, will allow Poniard ... to $60 million aggregate amount of its common stock, ...
... Fate Therapeutics, Inc. announced today ... owned by Children,s Hospital Boston and Massachusetts General Hospital. ... supporting hematopoietic stem cells. These proprietary technologies developed ... Program at Children,s Hospital Boston and a scientific founder ...
... CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic ... or the,Company,), one of the leading plasma-based pharmaceutical ... announced that the Company,s,management will present at the ... in New York, NY on May 18, 2009 ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... McGill University and the Quebec government have discovered ... Canadian Journal of Fisheries and Aquatic Sciences . ... cleansers, or industrial cleansers, to which they are ... size and buoyancy, they may readily pass through ... contaminant in the world,s oceans, but have only ...
(Date:9/18/2014)... information is stored in DNA, tiny strands of nucleic ... bodies. To express this genetic data, our DNA is ... into proteins that perform tasks in our cells. ... of RNA molecule. Unlike all other known RNAs, this ... circRNA molecules are abundant, little has been known about ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... of organic produce increases with consumers, growers need more ... and Gary R. Cline (retired) of the Land Grant ... designed to investigate options for reducing the presence of ... roots, shoots, and flowers, and transmit the bacterial wilt ...
... and the Society for Mycotoxin Research have signed an ... , the official journal of the Society. Aimed ... the journal deals with all topics related to mycotoxins, ... issue will appear in March 2009. High-quality original ...
... a $2.9 million, three-year grant from the Minerals Management ... at Austin marine scientists will assess the biological and ... before the area opens for offshore oil drilling. ... Interior) brings together several highly experienced Arctic scientists from ...
Cached Biology News:Controlling cucumber beetles organically 2Mycotoxin Research joins Springer's life sciences journals program 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 3
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Biology Products: